Syntekabio has entered into an agreement with CHA Hospital to jointly develop immunotherapy agents by using its artificial intelligence (AI) platform Deep Matcher. Under the terms, the two institutions will research developing a combination therapy for immune gateway inhibitors. The agreement came after the two parties signed a contract to co-develop STB001, an immunotherapy agent developed using Syntekabio's AI drug discovery platform.